Microbot Medical is making the commercial debut of its Liberty robot at the Society of Interventional Radiology annual conference this week, marking the first FDA-cleared single-use, remotely operated system for peripheral endovascular procedures to enter clinical practice in the United States. The launch lands during a period of broad expansion across surgical robotics: Medtronic’s Hugo is building its first US commercial footprint, J&J’s Ottava is in FDA review, and Intuitive Surgical has cleared nine new cardiac surgery indications. For founders building surgical devices or adjacent enabling technology, the market is moving across multiple clinical specialties at once.
Microbot Medical Brings the First Endovascular Robot Into Clinical Practice
Microbot Medical received FDA clearance for the Liberty system in September 2025, making it the first single-use, remotely operated robot cleared for peripheral endovascular procedures in the United States. The system targets procedures below the aortic bifurcation, a segment of vascular surgery where the skills gap between procedure demand and available trained operators has become a genuine bottleneck at hospital systems around the country.
The commercial launch at the Society of Interventional Radiology conference in April 2026 represents the company’s full market entry after a controlled pre-commercial phase. To support the rollout, Microbot exercised investment options with a potential value of up to $92.2 million, according to reporting from MassDevice. That capital is going toward the commercial infrastructure needed to support hospital accounts beyond early adopters, including field support and training programs.
For founders building in the interventional radiology adjacency, the Liberty launch matters beyond Microbot’s own market position. It establishes that the endovascular robotics category is moving from development to commercial practice, which changes the landscape for integration partners, imaging system developers, and capital equipment vendors working in the same clinical environment. The first cleared system in a category is always the procurement signal that hospital accounts were waiting for before engaging seriously.
Medtronic’s Hugo Builds Early Commercial Footing at US Academic Centers
Medtronic completed its first US procedure with the Hugo robotic-assisted surgery system in early February 2026, with a prostatectomy performed at Cleveland Clinic, according to MedTech Dive. Early commercial sites include Duke University Hospital and Atrium Health Wake Forest Baptist High Point Medical Center, with Atrium Health being the first non-study institution to install the system.
Hugo received FDA clearance in December 2025 for urologic procedures after completing the largest US study for robotic-assisted urological surgery, with a 98.5 percent surgical success rate against an 85 percent performance goal. Gynecologic and general surgery indications are planned as next expansions. The company’s rollout strategy is deliberately focused on leading academic and health system institutions rather than broad hospital adoption, building reference accounts and trained surgeon communities before moving into the broader market.
The conservative early-stage approach reflects what competing against Intuitive’s installed base actually requires. Credible references at recognizable institutions change the procurement conversation at every subsequent account. Companies that skip this step tend to find the sales cycle longer and harder than it needed to be.
J&J’s Ottava Is in FDA Review and the Market Has Not Priced In a Third Platform Yet
Johnson & Johnson submitted its Ottava robotic surgery system for FDA de novo classification in January 2026, targeting general surgery applications. A clearance decision would introduce a third credible large-platform competitor into a market that has operated as a one-company environment for soft tissue surgery for more than two decades.
Hospital procurement teams are already beginning to hold conversations that were not possible two years ago. Accounts that deferred robotics investment while waiting for competitive alternatives now have the prospect of evaluating three platforms with different clinical footprints, pricing structures, and ecosystem strategies. For founders building surgical instruments, imaging systems, or workflow software that runs alongside these platforms, the platform selection question now has real implications for integration roadmaps and partnership sequencing.
Intuitive Surgical Extends Da Vinci Into Cardiac Surgery
Intuitive Surgical added nine new FDA-cleared indications for cardiac surgery in early 2026, including mitral and tricuspid valve repair, according to MedTech Dive’s analysis of 2026 robotic surgery trends. The company is projecting worldwide da Vinci procedure growth of 13 to 15 percent for the year, down from 18 percent in the prior period but still representing meaningful expansion across a large installed base.
The cardiac expansion is significant because it extends robotic assistance into procedures where open surgery has remained the standard despite its complexity and recovery burden. The mitral valve repair indication addresses a procedure with a known skills concentration problem in the cardiothoracic surgery community, the same dynamic that drove robotic adoption in urology and then gynecology. For founders building in cardiac adjacencies, the cleared indication set creates a reference pathway for clinical trial design and regulatory submissions targeting the same procedure category.
Dave’s take
What I keep coming back to is how much is happening at once. Soft tissue, spine, endovascular, cardiac, ophthalmology, ENT — the market is not expanding sequentially. It is expanding in parallel, and each specialty has its own procurement dynamics, evidence requirements, and clinical champion profile. The founders I work with who are building enabling devices or workflow software for robotic procedures need to be very specific about which clinical environment they are actually building for. That answer changes what evidence you need, who makes the purchase decision, and what timeline you are working against. Building for a category is not a strategy. Building for a specific clinical problem in a specific care setting with a specific evidence plan is.
I’m here to help you scale.
Work With Dave